• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

《晚间和晨间行为日常父母评定量表修订版的信度和效度》。

Reliability and Validity of the Daily Parent Rating of Evening and Morning Behavior Scale, Revised.

机构信息

1 SUNY Upstate Medical University, Syracuse, NY, USA.

2 Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV, USA.

出版信息

J Atten Disord. 2018 Sep;22(11):1066-1073. doi: 10.1177/1087054715619009. Epub 2015 Dec 23.

DOI:10.1177/1087054715619009
PMID:26700792
Abstract

OBJECTIVE

Children with ADHD frequently manifest behavioral difficulties in the morning prior to school. We sought to assess the reliability and validity of the Daily Parent Rating of Evening and Morning Behavior Scale, Revised (DPREMB-R) morning score as a measure of morning behaviors impaired by ADHD.

METHOD

We used data from a clinical trial of HLD200 treatment in pediatric participants with ADHD to address our objectives.

RESULTS

The DPREMB-R morning score showed significant internal homogeneity, test-retest reliability ( r = .52-.45), and good concurrent validity ( r = .50-.71).

CONCLUSION

The DPREMB-R morning score could be a useful instrument for assessing treatment efficacy in the morning before school.

摘要

目的

患有注意力缺陷多动障碍(ADHD)的儿童在上学前的早晨经常表现出行为困难。我们试图评估修订后的日常家长评定的晚间和晨间行为量表(DPREMB-R)晨间评分作为衡量 ADHD 导致晨间行为障碍的可靠有效方法。

方法

我们使用了 ADHD 儿科参与者 HLD200 治疗临床试验的数据来解决我们的目标。

结果

DPREMB-R 晨间评分显示出显著的内部同质性、测试-重测可靠性(r =.52-.45)和良好的同时效度(r =.50-.71)。

结论

DPREMB-R 晨间评分可能是一种有用的工具,可用于在上学前的早晨评估治疗效果。

相似文献

1
Reliability and Validity of the Daily Parent Rating of Evening and Morning Behavior Scale, Revised.《晚间和晨间行为日常父母评定量表修订版的信度和效度》。
J Atten Disord. 2018 Sep;22(11):1066-1073. doi: 10.1177/1087054715619009. Epub 2015 Dec 23.
2
Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.一日一次服用托莫西汀治疗注意缺陷/多动障碍儿童,包括对早晚行为的评估:一项双盲、安慰剂对照试验。
Pediatrics. 2004 Jul;114(1):e1-8. doi: 10.1542/peds.114.1.e1.
3
Reliability and Validity of the Before-School Functioning Scale in Children With ADHD.注意缺陷多动障碍儿童课前功能量表的信度和效度。
J Atten Disord. 2018 Sep;22(11):1040-1048. doi: 10.1177/1087054714564623. Epub 2015 Jan 9.
4
A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.一项针对台湾患有注意力缺陷/多动障碍的儿童和青少年每日一次服用托莫西汀的随机、双盲、安慰剂对照临床试验。
J Child Adolesc Psychopharmacol. 2007 Aug;17(4):447-60. doi: 10.1089/cap.2006.0091.
5
Functional Impairment in Youth With ADHD: Normative Data and Norm-Referenced Cutoff Points for the Before School Functioning Questionnaire and the Parent Rating of Evening and Morning Behavior Scale, Revised.注意缺陷多动障碍青少年的功能障碍:上学前功能问卷和父母评定的夜间和清晨行为量表修订版的常模数据和常模参照截断值。
J Clin Psychiatry. 2019 Dec 10;81(1):19m12956. doi: 10.4088/JCP.19m12956.
6
Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.成人注意力缺陷/多动障碍每日一次服用托莫西汀:一项为期6个月的双盲试验。
J Clin Psychopharmacol. 2009 Feb;29(1):44-50. doi: 10.1097/JCP.0b013e318192e4a0.
7
Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.盐酸托莫西汀治疗患有注意力缺陷/多动障碍及共病对立违抗性障碍的儿童和青少年:一项意大利的安慰剂对照研究。
Eur Neuropsychopharmacol. 2009 Nov;19(11):822-34. doi: 10.1016/j.euroneuro.2009.07.008. Epub 2009 Aug 28.
8
A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.一项随机双盲研究比较托莫西汀与安慰剂治疗自闭症谱系障碍儿童注意缺陷/多动障碍症状的疗效。
J Am Acad Child Adolesc Psychiatry. 2012 Jul;51(7):733-41. doi: 10.1016/j.jaac.2012.04.011. Epub 2012 May 25.
9
Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.缓释和长效释放型哌甲酯(HLD200)治疗注意缺陷/多动障碍儿童的疗效与安全性
J Child Adolesc Psychopharmacol. 2017 Aug;27(6):474-482. doi: 10.1089/cap.2017.0084. Epub 2017 Jul 21.
10
Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing.每日一次服用托莫西汀治疗儿童注意缺陷多动障碍:早晨与晚上给药的比较。
Clin Pediatr (Phila). 2009 Sep;48(7):723-33. doi: 10.1177/0009922809335321. Epub 2009 May 6.

引用本文的文献

1
Real-World Efficacy and Safety of Extended-Release Methylphenidate (PRC-063) in the Treatment of ADHD in Pediatric and Adult Subjects: Results of a Phase IV Multicenter Comparison With Lisdexamfetamine Dimesylate.真实世界中 PRC-063 缓释哌甲酯治疗儿童和成人 ADHD 的疗效和安全性:与赖氨酸安非他命二甲酸盐的 IV 期多中心比较结果。
J Atten Disord. 2023 May;27(7):743-756. doi: 10.1177/10870547231172767. Epub 2023 May 5.
2
Clinically Meaningful Improvements in Early Morning and Late Afternoon/Evening Functional Impairment in Children with ADHD Treated with Delayed-Release and Extended-Release Methylphenidate.接受延迟释放和缓释哌甲酯治疗的 ADHD 儿童在清晨和傍晚/晚间的功能障碍方面有临床意义上的改善。
J Atten Disord. 2022 Mar;26(5):696-705. doi: 10.1177/10870547211020073. Epub 2021 Jun 4.
3
Effect of Delayed-Release and Extended-Release Methylphenidate on Caregiver Strain and Validation of Psychometric Properties of the Caregiver Strain Questionnaire: Results from a Phase 3 Trial in Children with Attention-Deficit/Hyperactivity Disorder.延迟释放和延长释放哌甲酯对照顾者负担的影响及照顾者负担问卷心理测量学特性的验证:来自儿童注意缺陷多动障碍 3 期试验的结果。
J Child Adolesc Psychopharmacol. 2021 Apr;31(3):179-186. doi: 10.1089/cap.2020.0159. Epub 2021 Apr 1.
4
A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings.一项随机、双盲、安慰剂对照研究评估 HLD200(一种控释和缓释哌甲酯)治疗注意缺陷多动障碍儿童的安全性和疗效:全天和跨环境的评估。
J Child Adolesc Psychopharmacol. 2020 Feb;30(1):2-14. doi: 10.1089/cap.2019.0070. Epub 2019 Aug 29.
5
Outcome domains and outcome measures used in studies assessing the effectiveness of interventions to manage non-respiratory sleep disturbances in children with neurodisabilities: a systematic review.用于评估干预措施在管理神经发育障碍儿童非呼吸性睡眠障碍有效性的研究中使用的结局指标和结局测量:系统评价。
BMJ Open. 2019 Jun 19;9(6):e027205. doi: 10.1136/bmjopen-2018-027205.
6
Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.缓释和长效释放型哌甲酯(HLD200)治疗注意缺陷/多动障碍儿童的疗效与安全性
J Child Adolesc Psychopharmacol. 2017 Aug;27(6):474-482. doi: 10.1089/cap.2017.0084. Epub 2017 Jul 21.